Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

This publication has 30 references indexed in Scilit:

• Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa
  The Journal of Infectious Diseases, 2008
• The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
  The Journal of Experimental Medicine, 2008
• An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
  The Journal of Experimental Medicine, 2008
• Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses
  The Journal of Experimental Medicine, 2007
• Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy
  Vaccine, 2007
• Immunisation with recombinant modified vaccinia virus Ankara expressing HIV‐1 gag in HIV‐1‐infected subjects stimulates broad functional CD4⁺ T cell responses
  European Journal of Immunology, 2006
• Induction of long‐lasting multi‐specific CD8⁺ T cells by a four‐component DNA‐MVA/HIVA‐RENTA candidate HIV‐1 vaccine in rhesus macaques
  European Journal of Immunology, 2006
• Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
  Proceedings of the National Academy of Sciences, 2006
• Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine
  Journal of Virology, 2006
• Modified Vaccinia Ankara: Potential as an Alternative Smallpox Vaccine
  Clinical Infectious Diseases, 2004